Exozymes Inc. · NASDAQ:EXOZ
Exozymes — Investor Presentation (April 2026)
20 slides from Exozymes's investor presentation, Apr 10, 2026
Slide 1: The Next Generation of Biomanufacturing
= eXoZymes The Next Generation of Biomanufacturing NASDAQ: EXOZ
Slide 2: eXoZymes' Safe Harbor
eXoZymes’ Safe Harbor This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can general
Slide 3: Our Journey & Milestones
OUR JOURNEY & MILESTONES X) From Big Ideas Lab Invention to $200B+ Commercial Opportunity at hand. Adisciplined, highly capital-efficient journey from UCLA spinout to NASDAQ-listed leader of next generation biomanufacturing NCT & Cannabinoids at Invizyne/eXoZymes IPO on NASDAQ (EXOZ) scale with New
Slide 4: Flagship Product Programs
FLAGSHIP PRODUCT PROGRAMS Targeting validated master regulators of known biological pathways — the highest-leverage molecules driving pharma interest and nutraceutical demand yA Y NCT / Metabolic Health Cannabinoid Molecules Master regulator of cellular metabolism Master regulator of cellular signal
Slide 5: Cell-Free Is Synbio's Future
CELL-FREE IS SYNBIO’S FUTURE We Solved the Biomanufacturing Bottleneck Holding Back Entire Industries Synthetic biology promised to replace petrochemicals. But genetically engineering living cells into “chemical factories” did not work and it did not scale. eXoZymes Delivers: Idea to Pilot in <12 mo
Slide 6: The Breakthrough in Biomanufacturing: Why Not Skip the Cell?
THE BREAKTHROUGH IN BIOMANIFACTURING Why Not Skip the Cell? Cells make enzymes, Does the actual work Al-optimized and Scalable, controllable but cells stop if being used of building chemical stabilized to work commercial for chemical production molecules outside the cell biomanufacturing
Slide 7: Demonstrated Success
DEMONSTRATED SUCCESS Cell-Free Platform Makes Products No One Else Can with Impressive Profit and Purity Profiles & Beyond Synthetic Chemistry Exozymes leverage nature’s diversity — but with engineering- level control = Beyond Fermentation Exozymes have no living cell elements doing other things. Ul
Slide 8: Development Pipeline
DEVELOPMENT PIPELINE From Prototype to Value Creation: In Months, Not Years Prototyping Incubation Acceleration Commercialization 3-9 weeks 3-6 months 6-12 months 6-18 months Lab feasibility Business intel + cost Pilot scaling and Spinout or license, first demonstrated feasibility validated sampling
Slide 9: Proven Results: NCT
PROVEN RESULTS: NCT eXoZymes Makes NCT at Scale Concept to Pilot Scale in < 1 year + Successful Tech Transfer 99% Reaction Yield Industry-leading efficiency at pilot scale 18X Production Cycle Faster than conventional SOTISED ULC pilot Seale manufacturing approaches in <1 year Unlocks consistent, co
Slide 10: NCT: A New Metabolic Wellness Category
NCT: A NEW METABOLIC WELLNESS CATEGORY NCT NG I N-trans-caffeoyltyramine (NCT): a rare plant-derived compound with emerging relevance in metabolic health, gut integrity, and liver function The Bottleneck We Solved In Nature only found at <14 ppm y 100x scale-up with >99% conversion — partner-execute
Slide 11: Cannabinoid Opportunity
CANNABINOID OPPORTUNITY The Purity & Non-Intoxication Manufacturing Bottlenecks We Overcame Now producing rare and new-to-nature cannabinoids at commercial scale with GMP purity * Cannabinoid receptors are present on nearly every cell in the body * Nature supplies a messy mix of intoxicating and non
Slide 12: Value Creation Discipline
VALUE CREATION DISCIPLINE How We Choose the Right Molecules ¢ We apply rigorous selection criteria before committing to any new molecule ¢ Dual screening: strong R&D viability + high business potential ¢ Balanced against key factors: Unique IP Huge Market Profitable opportunity Ownership Potential M
Slide 13: Go-to-Market Strategy
GO-TO-MARKET STRATEGY & Tech Transfer Package eXoZymes delivers a complete, validated biomanufacturing system and protocol — while retaining full platform IP CMO Scale-Up & Production eXoZymes and partners qualify leading CMOs for capital-light scale-up and manufacturing infrastructure iQ Partners S
Slide 14: Upcoming Catalysts
UPCOMING CATALYSTS Value-Creating Events on the Horizon = Cannabinoids Technology transfer package delivery to contract manufacturer for GMP-scale production Commercial partnerships with global nutritional supplement marketers for OTC product launch Partnering with pharmaceutical companies to initia
Slide 15: Financial Overview
FINANCIAL OVERVIEW $15M ~$10M $17M $B+ Potential Raised at Nasdaq IPO Annual Operating (November 2024) Expenses Total Grant Funding Multi Billion Basic Research and (Metbeu Upsisle New Platforms
Slide 16: Leadership Team
LEADERSHIP TEAM Experienced Management Michael Heltzen = ceo Serial biotech entrepreneur. Leads strategic, company culture & executional excellence. Dr. Tyler Korman cso & Co-Founder PhD in structural biology. Expert in enzyme catalysis R&D. Co-invented the platform at UCLA. Dr. Paul Opgenorth ve of
Slide 17: Capital Raise
CAPITAL RAISE @ Use of Proceeds —for Core Platform + NCTX Capital raise of $10M - $15M depending on pricing Approx. SHARE of CATEGORY) AMOUNT $15M Raise Core NCT Platform Flagship Core Platform ~$10M NCT Product [BB Working capital & Operations ~$3.5M 23% Scale-Up Program [BB Cannabinoids &next-in-l
Slide 18: Investment Thesis
INVESTMENT THESIS Why eXoZymes Now Only Cell-Free Platform a wy $200B+ Combined TAM rv) Validated at Scale $300B+ Patent Cliff Capital-Light Model " Months, Not Years
Slide 19: Offering Summary
eXoZymes Offering Summary Learn More * Offering Size: $10 million - $15 million * Pricing: TBD * NASDAQ ticker: EXOZ * QSBS: Management believes the offering qualifies for Section 1202/QSBS exclusion” Indications of Interest *You should consult your own tax, legal and accounting advisors before enga
Slide 20: Thank you.
eXoZymes NASDAQ: EXOZ Thank you. info@exozymes.com * exozymes.com eXoZymes Inc. Next Gen. Biomanufacturing: Transforming rare, previously unscalable biochemistry into predictable, high-purity natural products and next-generation drugs.